Mode
Text Size
Log in / Sign up
Early Phase 1 Completed N=80 Randomized Single-blind

Human Tissue Distribution of Orally Supplemented Natural Vitamin E Tocotrienol

End Stage Cardiac Failure · Pulmonary Failure · End Stage Liver Disease · Morbid Obesity
Source: ClinicalTrials.gov NCT00678834 ↗
Enrolled (actual)
80
Serious AEs
0.0%
Results posted
Sep 2014
Primary outcomePrimary: The Levels of TCT in the Tissues of "Non-healthy" Subjects and in the Tissue of "Healthy" Subjects Following Oral Supplementation (200 mg x 2 Per Day for 4-24 Weeks) — 9.94; 1.29; 5.37; 0.42 nmol/g

Summary

Levels of tocotrienol in human tissues following supplementation is not currently known. The objective of this present study is to determine the levels of this form of vitamin E in the human tissues such as skin, heart, lung, liver, adipose tissue, Brain and cerebrospinal fluid (CSF) following oral supplementation

Outcome Measures

OutcomeResultp-value
PRIMARY
The Levels of TCT in the Tissues of "Non-healthy" Subjects and in the Tissue of "Healthy" Subjects Following Oral Supplementation (200 mg x 2 Per Day for 4-24 Weeks)
9.94; 1.29; 5.37; 0.42; 28.6; 50.5

Eligibility Criteria

Aim 1 Surgical candidate with a surgery schedule date with a time period of 4-24 weeks (<4 weeks will be excluded; last dose until 24h before surgery) In Aim 1 we expect to have patients, with diverse co-morbidity and medication conditions.

Patient Selection: Because of limitation in obtaining healthy human tissues (as in Aim 2), we plan to obtain these tissues from patients who are scheduled for the following surgeries for subjects in group one:

Heart Heart Transplant Heart Failure- Biopsy taken from diseased heart Lung Lung Transplant, Lung-wedge/resection, Lobectomy Cancer- Tissue sample taken from removed lung or resected portion of lung Liver Liver Transplant, Biopsy, Resection Hepatic Malignancy- Biopsy taken from resected portion of liver Adipose Tissue Panniculectomy Excessive Tissue of the Abdomen Brain & CSF Epilepsy Excised brain tissue and cerebrospinal fluid

To ensure higher enrollment we are not controlling for age of subjects as long as the subjects are 21 years of age or older.

Inclusion Criteria Aim 1:

  • age 21 and older
  • good health
  • non- smoker
  • no current medications
  • non- pregnant or non-breastfeeding
  • no previous use of OTC medications or other form of supplements containing vitamin-E.

Inclusion Criteria Aim 2:

  • age 21 - 40 years
  • good health
  • non- smoker
  • no current medications
  • non- pregnant or non-breastfeeding
  • no previous use of OTC medications or other form of supplements containing vitamin-E.

Exclusion Criteria Aim 1:

  • Long-term use of OTC medications containing vitamin-E or current vitamin-E supplements
  • Scheduled surgery date lesser than 4 weeks or greater than 24 weeks.

Exclusion Criteria Aim 2:

  • Over 40 or under 21 years of age
  • Current smoker
  • Pregnant and breastfeeding
  • Diabetes and HIV diagnosis
  • Immunosuppression therapy
  • Any neurological problems
  • Long-term use of OTC medications containing vitamin-E or current vitamin-E supplements
  • ETOH or drug abuse
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00678834). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search